<DOC>
	<DOCNO>NCT01588821</DOCNO>
	<brief_summary>This research study Phase II clinical trial . Phase II clinical trial test effectiveness investigational drug learn whether drug work treat specific cancer . `` Investigational '' mean drug still study research doctor try find it-such safest dose use , side effect may cause , drug effective treat different type cancer . It also mean FDA approve drug type cancer , use outside research study . When cancer spread primary tumor , one common sit spread bone . When cancer spread bone significant symptom pain . Cabozantinib work block signal lead cancer growth well block growth new blood vessel ( angiogenesis ) help fee tumor . Cabozantinib study study research study possible treatment various type cancer , include prostate cancer , brain cancer , thyroid cancer , lung cancer kidney cancer . Previous clinical research study indicate cabozantinib may also activity cancer spread bone . The purpose study find cabozantinib effective treating cancer spread bone .</brief_summary>
	<brief_title>Cabozantinib Advanced Solid Malignancies</brief_title>
	<detailed_description>Cabozantinib tablet subject take mouth . The subject take per day . The study treatment cabozantinib divide 28 day cycle . A member study staff give subject drug diary explain subject use record dose cabozantinib . This diary also contain specific instruction subject take cabozantinib . Every 28 day subject undergo following procedure : Physical examination , question side effect subject may , blood sample routine laboratory test research test , urine sample , electrocardiogram ( EKG ) , questionnaires measure quality life level pain . Every two month subject undergo CT scan MRI evaluate subject disease . The investigator would like subject return study clinic follow-up procedure 4-5 week last dose cabozantinib . The subject continue receive study drug long disease worsen subject experience unacceptable side effect .</detailed_description>
	<criteria>Histologic cytologic diagnosis solid tumor ( breast prostate ) metastatic refractory progress follow standard therapy Has bony metastasis Agree use medically accept method contraception Pregnant breastfeeding Received cytotoxic chemotherapy ( include investigational cytotoxic chemotherapy ) biologic agent within 3 week study entry ( 6 week nitrosoureas/mitomycin C ) Received radiation thoracic cavity/GI tract ( within 3 month study entry ) , bone brain metastasis ( within 14 day ) site within 28 day Received prior treatment small molecule kinase inhibitor hormonal therapy within 14 days/5 halflives Received therapy another investigational agent within past 28 day Has recover toxicity due prior therapy Primary brain tumor Active brain metastases epidural disease Uncontrolled significant intercurrent recent illness Allergy hypersensitivity component study treatment formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
</DOC>